Compositions for the treatment of skin conditions
AssigneeDermata Therapeutics, Inc.
InventorsGerald Thomas Proehl, Christopher Joseph Nardo
Life of this patent
Estimating the term…
Loading patent…
AssigneeDermata Therapeutics, Inc.
InventorsGerald Thomas Proehl, Christopher Joseph Nardo
Estimating the term…
The present disclosure relates to the treatment of a skin condition in a subject, including but not limited to one or more of luminosity, brightness, skin pore size, skin pore count, sebum production, sebum composition, overall skin quality, eyelid laxity, fine lines under the eye, fine lines on the face, laxity on the face, perioral rhytids, moderate to severe facial folds and wrinkles such as nasolabial folds, moderate to severe facial wrinkles such as smile lines or marionette lines, age-related midface contour deficiencies, dorsal hand to correct volume deficit, glabellar lines, correction of facila depressions, either due to injury or age-related, perioral wrinkles, lip commissures, crow's feet, facial rhytides, and forehead wrinkles, comprising applying to the skin of the subject a first composition derived from one or more sponges, and a second composition comprising one or more botulinum toxins. Also provided are compositions for use in the treatment of a skin condition in a subject, including but not limited to hyperhidrosis, comprising a first composition and a second composition, wherein (a) the first composition comprises Spongilla; and (b) the second composition comprises one or more botulinum toxins. Also provided are kits, including kits for the treatment of a skin condition in a subject including but not limited to hyperhidrosis, comprising a first composition and a second composition, wherein the first composition comprises Spongilla, and the second composition comprises one or more botulinum toxins.
A topical pharmaceutical composition for topically administering and treating hyperhidrosis in a subject in need thereof, comprising a combination comprising a first topical pharmaceutical composition and a second topical pharmaceutical composition, wherein (a) the first topical pharmaceutical composition comprises Spongilla particles, the particles consisting of Spongilla spicules having an aspect ratio of from 10 to 70, an average length of about 200 μm to about 350 μm, and an average diameter of about 5 μm to about 20 μm, wherein the Spongilla particles are irradiated and are manufactured from Spongilla lacustris;
A kit, comprising a combination comprising a first topical pharmaceutical composition and a second topical pharmaceutical composition, wherein:
Dependencies are inferred from the claim text.